Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.
Botanix Pharmaceuticals has scheduled its 2025 Annual General Meeting for November 20, 2025, in Perth, Western Australia. A key agenda item is the re-election of directors, with nominations closing on October 2, 2025. This meeting is significant for stakeholders as it may influence the company’s governance and strategic direction.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US, known for its FDA-approved product Sofdra™, which treats primary axillary hyperhidrosis. Sofdra™ is the first new chemical entity approved for this condition, offering a novel and effective solution for patients lacking treatment options.
Average Trading Volume: 15,484,804
Technical Sentiment Signal: Sell
Current Market Cap: A$294.2M
See more insights into BOT stock on TipRanks’ Stock Analysis page.